Tag Archives: Jason Mccarthy

Maxim Group Reaffirms Their Buy Rating on Cassava Sciences Inc (SAVA)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences Inc (SAVA – Research Report) yesterday and set a price target of $3. The company’s shares closed last Monday at $1.30. McCarthy wrote: “Cassava announced the initiation of

Maxim Group Remains a Buy on Mesoblast Ltd (MESO)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Mesoblast Ltd (MESO – Research Report) on September 10 and set a price target of $16. The company’s shares closed last Monday at $6.54. According to TipRanks.com, McCarthy ‘s ranking

ReNeuron Group plc (RNUGF) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating on ReNeuron Group plc (RNUGF – Research Report) on September 10 and set a price target of $6. The company’s shares closed last Monday at $2.53. According to TipRanks.com, McCarthy is

Cassava Sciences Inc (SAVA) Gets a Buy Rating from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cassava Sciences Inc (SAVA – Research Report), with a price target of $3. The company’s shares closed last Monday at $1.21. McCarthy said: “Cassava reported

Maxim Group Keeps Their Buy Rating on Soligenix (SNGX)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Soligenix (SNGX – Research Report), with a price target of $4. The company’s shares closed last Monday at $1.10. McCarthy observed: “Soligenix announced that the

Maxim Group Maintains a Buy Rating on ADMA Biologics (ADMA)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics (ADMA – Research Report), with a price target of $12. The company’s shares closed last Monday at $4.35. McCarthy noted: “ADMA announced (8/22)